Topical Corticosteroids — source conflicts

Conflict: [AFP Cochrane for Clinicians, 2023] lists desonide 0.05–0.1% as medium and triamcinolone 0.1% as high potency. [AFP Ference & Last, 2009] places desonide in US group VI (low), and [DermNet, n.d.] lists triamcinolone acetonide as moderate. Potency tier for the same molecule varies by classification/vehicle. Unresolved — add to open_questions.

Conflict: [AFP summarising AAD 2014, 2023] says AAD recommends twice-daily TCS (once may suffice). [Cochrane, Lax 2022] finds once daily probably as effective; [NICE CG57] allows either. AAD 2023 update covers adults only. Unresolved — add to open_questions.

Conflict: [DermNet, n.d.] says systemic effects need very large long-term quantities (>50 g clobetasol/week). [Axon et al., BMJ Open 2021] reports reversible biochemical adrenal suppression in 3.8% of children (any potency, observational) and 2/44 children on potent weekend therapy. Unresolved — add to open_questions.

Conflict: [Axon et al., BMJ Open 2021] and [Cochrane, Lax 2022] found no evidence of harm from intermittent/weekend TCS. [Ahuja & Lio, Pediatric Dermatology 2025] report paediatric TSW cases with use patterns ranging down to twice-weekly use. Unresolved — add to open_questions.